Coherus Oncology, Inc.
CHRS
$1.59
$0.010.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.75M | 11.57M | 10.25M | 7.60M | 7.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.75M | 11.57M | 10.25M | 7.60M | 7.73M |
| Cost of Revenue | 4.05M | 3.72M | 3.40M | 2.65M | 2.75M |
| Gross Profit | 8.70M | 7.85M | 6.86M | 4.95M | 4.98M |
| SG&A Expenses | 21.01M | 22.83M | 26.04M | 26.03M | 29.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.03M | 53.80M | 55.74M | 53.03M | 53.12M |
| Operating Income | -43.28M | -42.23M | -45.49M | -45.44M | -45.38M |
| Income Before Tax | -46.35M | -44.52M | -44.86M | -47.40M | -46.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.35M | -44.52M | -44.86M | -47.40M | -46.09M |
| Earnings from Discontinued Operations | 8.70M | 8.99M | 342.63M | -9.17M | -4.60M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.64M | -35.53M | 297.77M | -56.57M | -50.70M |
| EBIT | -43.28M | -42.23M | -45.49M | -45.44M | -45.38M |
| EBITDA | -42.38M | -41.27M | -44.47M | -44.39M | -44.35M |
| EPS Basic | -0.31 | -0.31 | 2.57 | -0.49 | -0.44 |
| Normalized Basic EPS | -0.23 | -0.23 | -0.24 | -0.26 | -0.25 |
| EPS Diluted | -0.31 | -0.31 | 2.57 | -0.49 | -0.44 |
| Normalized Diluted EPS | -0.23 | -0.23 | -0.24 | -0.26 | -0.25 |
| Average Basic Shares Outstanding | 120.37M | 116.23M | 116.08M | 115.86M | 115.42M |
| Average Diluted Shares Outstanding | 120.37M | 116.23M | 116.08M | 115.86M | 115.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |